Bing

SEARCH HISTORY

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). Details of any securities borrowing and lending positions or
The Wall Street Transcript · 6/30/2015
Allos Therapeutics ($ALTH) announced this morning that a merger agreement with AMAG ($AMAG) has been was terminated. The termination comes after a special meeting of AMAG stockholders, who voted against the issuance of shares of the …
FiercePharma · 10/21/2011
Stock symbols are in parentheses ... projecting more sales and profit than analysts estimate. Allos Therapeutics Inc. (ALTH) slumped 13 percent to $5.78 and tumbled 17 percent earlier, the most intraday since December 2008. The cancer drug developer ...
Businessweek · ByLu Wang · 12/7/2009
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) (http ... Inc. (“Allos”) (NASDAQ:ALTH) shareholders who held Allos common stock during the period beginning July 20, 2011 through and including the closing …
Business Wire · 9/23/2011
ERTS – Electronic Arts, Inc. – Demand for call options on the video game ... Shares surged nearly 5% to $19.40, spurring heavier than normal options activity on the stock. Bullish investors stampeded toward the October contract right out of the gate ...
Forex Street · 9/23/2009
Stocks of wild Atlantic salmon have been reduced to dangerously ... Herring from the Western Baltic has also improved its status, alth-ough should still be eaten only sparingly. Some whiting, often suggested as a good alternative to cod and plaice, find ...
Wales Online · 9/30/2014
AMAG Pharmaceuticals ($AMAG) and Allos Therapeutics ($ALTH) struck a deal to merge in an all-stock transaction valued at $686 million. And the two developers have already identified $55 million to $60 million in "synergies" that they plan to quickly carve ...
Fierce Biotech · ByJohn Carroll · 7/20/2011
Nalco shares on the New York Stock Exchange climbed more than 23%. Shares of Allos Therapeutics (NASDAQ:ALTH) and AMAG Pharmaceuticals (NASDAQ:AMAG) dropped after the two announced they would merge in an all-share deal valued at $686 …
Proactive Investors Australia · 7/21/2011
Jason Kantor, Ph.D.RBC Capital Markets Corp.415-633-8565Jason.kantor@rbccm.com An increase in M&A among earlier-stage public [biotechnology] companies is likely and would enhance investor confidence in small-cap stocks. Large-cap companies …
Think Advisor · 9/1/2008
Stocks are holding up well against a barrage of bad macro news ... and it is on the way to a merger with Allos Therapeutics (ALTH), which will further expand the development pipeline.
globes.co.il · 7/9/2012